

# Bin-Chi Liao

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5789842/bin-chi-liao-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23  
papers

428  
citations

11  
h-index

20  
g-index

25  
ext. papers

562  
ext. citations

4.5  
avg, IF

3.93  
L-index

#	Paper	IF	Citations
23	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , <b>2015</b> , 27, 94-101	4.2	102
22	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1754-61	8.9	96
21	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Biomedical Science</i> , <b>2016</b> , 23, 86	13.3	35
20	Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. <i>Lung Cancer</i> , <b>2017</b> , 110, 7-13	5.9	31
19	Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 50-61	8.9	29
18	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. <i>European Journal of Cancer</i> , <b>2020</b> , 124, 110-122	7.5	28
17	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. <i>Therapeutic Advances in Medical Oncology</i> , <b>2015</b> , 7, 274-90	5.4	18
16	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. <i>Current Oncology Reports</i> , <b>2017</b> , 19, 4	6.3	12
15	First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. <i>Drugs</i> , <b>2013</b> , 73, 357-69	12.1	12
14	Second-line treatment of T790M-negative non-small cell lung cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919890286	5.4	12
13	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , <b>2020</b> , 25, 702-711	5.7	11
12	Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 137-43	4.9	8
11	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. <i>Journal of the Formosan Medical Association</i> , <b>2018</b> , 117, 326-331	3.2	7
10	CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , <b>2021</b> , 41, 1231-1242	2.3	7
9	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. <i>Journal of Cancer</i> , <b>2016</b> , 7, 1515-23	4.5	5
8	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 851-864	4	4
7	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.. <i>Clinical Cancer Research</i> , <b>2022</b> ,	12.9	4

6	A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS9631-TPS9631	2.2	2
5	Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6024-6024 <sup>2,2</sup>	2.2	2
4	Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis. <i>Medical Oncology</i> , <b>2017</b> , 34, 143	3.7	1
3	Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. <i>Translational Lung Cancer Research</i> , <b>2012</b> , 1, 227-9	4.4	
2	Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e19061-e19061	2.2	
1	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100099	1.4	